SIX1 and esophageal cancer: In line with our observations, inspection of datasets from the TCGA collection reveals a significant correlation between SIX1 and SOX2 expression in different tumor types, including glioma, soft-tissue sarcoma, prostate and esophageal cancer (Supplementary Fig. S8).